Jonathan Zalevsky - Aug 18, 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Chief R&D Officer
Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
Aug 18, 2022
Transactions value $
-$342,779
Form type
4
Date filed
8/19/2022, 06:27 PM
Previous filing
Aug 17, 2022
Next filing
Nov 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Sale -$343K -73.7K -18.39% $4.65* 327K Aug 18, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $4.56 to $4.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the Issuer.